SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ImmunityBio converts from Immunomedics
IBRX 2.110-1.4%Nov 6 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jargonweary who wrote (992)5/5/2025 12:38:26 PM
From: galt3 Recommendations

Recommended By
bobbseytwins2001
erippetoe
urslor

  Read Replies (1) of 1229
 
Unfortunately, this could lead to another class action suit. Just saying, but hoping not.
Agree that the volume today is suggesting that this might be about something else.
Hoping not, but, like Tinfoil, I'm using it to average down.
I do not think we're looking at years, but maybe months, to right the ship on other
indication trials. Given that Anktiva is already approved for one cancer, and has shown
very good early results on others, I'm ok adding more at this point.
Having said that, I'm kinda sure that mgmt. screwed up in some way.
I'm hoping politics is not a part of this, but in this crazy world, who knows.
Let's hope that we hear more, sooner rather than later.
Best
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News